Skip to content

GRAIL, Inc. GRAL Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Guardant Health logo
Guardant HealthGH
$1.1B+37.0%
Natera, Inc. logo
Natera, Inc.NTRA
$1.09B+11.7%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$525.86M+243%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$77.58M+53.2%

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s cash & equivalents?
GRAIL, Inc. (GRAL) reported cash & equivalents of $76.32M in Q1 2026.
How has GRAIL, Inc.'s cash & equivalents changed year-over-year?
GRAIL, Inc.'s cash & equivalents decreased by 44.4% year-over-year, from $137.24M to $76.32M.
What is the long-term trend for GRAIL, Inc.'s cash & equivalents?
Over 3 years (2022 to 2025), GRAIL, Inc.'s cash & equivalents has grown at a 1.4% compound annual growth rate (CAGR), from $246.13M to $256.7M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.